Biomarkers improve response rates
In both real world and clinical trial settings, a greater proportion of patients
benefit when selected by biomarkers
Immune checkpoint inhibitor response rate1:
Progression of drug to next clinical phase2:
Without using biomarkers to stratify patients
With using biomarkers to stratify patients
1 Late-stage gastric cancer cohort, checkpoint inhibitor monotherapy, described in: Strand-Tibbits K., et al. Society for ImmunoTherapy in Cancer, 2020.
2 Parker JL, et al. Cancer Medicine, 2021.
Biomarker discovery challenges
Biological complexity
Diseases are complex and patients are unique
ResponderID™:
- Determines which features to measure
- Constructs a model that learns signal and excludes noise
Disparate data sets
Evidence comes from all corners
ResponderID™:
- Weighs information content and consistency
- Harmonizes data across assay platforms, disease types, experimental models and clinical cohorts
Independent validation
Ensuring robustness on new patient data
ResponderID™:
- Confronts bias to enable cross-data comparisons
- Evaluates performance on retrospective, prospective and proxy data
Biomarkers for every segment of the life science industry
Genialis ResponderID™ drives collaborations for:
Therapeutic selection:
Identify patients with higher chance to respond to treatment
- Improve likelihood of achieving clinical endpoints and maximize clinical development program ROI
- Increase speed to successful trial conclusion (minimize late-stage failures) and reach commercialization/patient care faster
Indication expansion:
Prioritize additional therapeutic opportunities based on potentially responsive patient populations
- Expand market potential for drug
- Improve outcomes for more patients
Genialis ResponderID™ powers programs to:
Build prognostic or predictive testing
- Expand product line to cover more therapeutic settings and reach more patients
- Differentiate test offerings from other providers using machine learning
Create “flywheel” data products that compound in value
- Leverage new and existing data to attract more pharmaceutical business and energize novel business models
- Identify signatures that support translational research, clinical trials & companion diagnostic development
Genialis ResponderID™ inspires partnerships that allow you to:
Translate your data resources into meaningful outcomes
- Forge collaboration between clinical and translational R&D within your organization
- Impact patient lives through diagnostic and therapeutic product discovery
Advance your organization’s mandate through flexible
business models
- Attract biotech partners for sponsored research and licensing opportunities
- Publish high impact clinical research to disseminate knowledge and drive future grant funding
